EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS) ...

APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, ...

WASHINGTON -- Rheumatoid arthritis (RA) patients who achieved sustained remission had better long-term outcomes than those with lingering low-level symptoms, a single-center study found -- casting ...

In both NEPTUNUS-1 and NEPTUNUS-2, once monthly ianalumab 300mg improved ESSDAI scores vs placebo at week 48. Ianalumab significantly reduced disease activity in patients with Sjögren disease, ...

An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II study showed.

Findings showed both trials met the primary endpoint, demonstrating statistically significant improvement in Sjögren disease activity vs placebo. Topline data were announced from two phase 3 trials ...

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder. It is characterized by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as ...